Korean J Fam Pract 2023; 13(4): 247-248  https://doi.org/10.21215/kjfp.2023.13.4.247
[Correction] Recurrent Neural Network Based Drug Repurposing to Address SARS-CoV-2 (COVID-19), and the in vitro Antiviral Efficacy of Peroxisome Proliferator-Activated Receptors-Gamma Agonist
Nam Hee Kim, Jae June Dong*
Department of Family Medicine, Yonsei University College of Medicine, Seoul, Korea
Published online: December 20, 2023.
© The Korean Academy of Family Medicine. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


Korean J Fam Pract. 2021;11(4):312-321

본 학술지에 게재된 위 논문에서 Figure 정보에 오류가 있어 교체합니다.

This correction is being published to correct the Figures’ in above article.

After correction

Figure 1. The life cycle of SARS-CoV-2. ACE-2, angiotensin converting enzyme; Mpro, main protease; RdRp, RNA-dependent RNA polymerase.

Figure 2. Process of data based on simplified molecular-input line-entry system (SMILES). CORD-19, The Covid-19 Open Research Dataset; IOS, Initiation of string; EOS, end of string; LSTM, long short term memory.

Figure 3. Molecular docking simulation between SARS-CoV-2 main protease and RNA-dependent RNA polymerase using autodock vina. (A) Binding site of SARS-CoV-2 main protease. (B) Binding site of RNA-dependent RNA polymerase.

This Article